Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)
Clinical trial NCT02494583 · COMPLETED
Trial details
- NCT number
- NCT02494583
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-07-31
- Primary completion
- 2019-03-26
- Enrollment
- 763
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.